Aktuellt
SENASTE
Redeye see a Q3 report from Genovis that came in just above our estimates in terms of sales but delivered a solid beat on the EBIT level. The enzyme business continues to show encouraging growth on the back of increasing ADC-related volumes. We expect to make minor changes to our forecasts on the back of the report and also leave a short comment on Genovis' partner Selecta Biosciences which on Monday announced a merger.
LÄS MER
